News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Apthera, Inc. and TGen Drug Development Services (TD2) Sign Master Services Agreement


8/5/2008 9:09:59 AM

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Apthera, Inc., a Scottsdale, Arizona-based biotechnology company focused on cancer immunotherapy, today announced an alliance with TGen Drug Development Services (TD2) under a Master Services Agreement. TD2 will provide key drug development and regulatory services related to the clinical development of NeuVax™, Apthera’s lead immunotherapy drug indicated for the adjuvant treatment of early-stage, lymph-node-positive breast cancer that contains the HER2 oncogene. Apthera is currently preparing NeuVax for pivotal international Phase III clinical trials.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES